/DGCRF

DGCRF Stock - Diagnocure, Inc.

Q: What is the analyst price target for DGCRF?

Analyst price target information is not currently available for DGCRF.

Q: What is DGCRF's market cap?

Market capitalization information is not currently available for DGCRF.

Healthcare|Medical - Specialties|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jun 11

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DGCRF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2011

FY2012

FY2013

FY2014

FY2015

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-15.95

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2015	FY2014	FY2013	FY2012	FY2011
Revenue	$515,372	$553,140	$671,228	$2.47M	$1.24M
Gross Profit	$515,372	$553,140	$671,228	$1.50M	$-130,148
Gross Margin	100.0%	100.0%	100.0%	60.7%	-10.5%
Operating Income	$-1,515,318	$-2,084,688	$-3,631,472	$-3,756,748	$-4,485,458
Net Income	$-3,600,168	$-2,032,151	$-3,566,942	$-3,679,324	$-1,264,509
Net Margin	-698.6%	-367.4%	-531.4%	-148.8%	-101.8%
EPS	$-0.11	$-0.06	$-0.08	$-0.09	$-0.03

Company Overview

Diagnocure, Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test. It also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company was formerly known as DiagnoCure Inc. 9342-8530 Québec Inc. was founded in 1994 and is headquartered in Quebec, Canada.

Visit Website

Frequently Asked Questions about DGCRF

What is DGCRF's current stock price?

Diagnocure, Inc. (DGCRF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for DGCRF?

No analyst price targets are currently available for this stock.

What sector is Diagnocure, Inc. in?

Diagnocure, Inc. operates in the Healthcare sector, specifically within the Medical - Specialties industry. The company is traded on the OTC exchange.

What is DGCRF's market cap?

Diagnocure, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does DGCRF pay dividends?

No, Diagnocure, Inc. does not currently pay a dividend to shareholders.